HeartFlow
Founded Year
2007Stage
Series F - II | AliveTotal Raised
$757.41MLast Raised
$215M | 2 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+5 points in the past 30 days
About HeartFlow
HeartFlow provides a digital health service platform for heart disease diagnosis and treatments. It offers a non-invasive personalized cardiac test that provides unprecedented visualization of each patient’s coronary arteries, enabling physicians to create treatment plans for their patients. The company was formerly known as Cardiovascular Simulation. It was founded in 2007 and is based in Mountain View, California.
Loading...
HeartFlow's Product Videos
ESPs containing HeartFlow
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The radiology AI — cardiac CT analytics market is focused on improving the diagnosis and management of heart disease through the use of artificial intelligence and advanced imaging technologies. Companies in this market use AI to accurately detect and analyze features such as coronary artery stenosis, ventricular hypertrophy, and other anomalies that can be indicative of cardiac-related diseases. …
HeartFlow named as Leader among 10 other companies, including Cleerly, Medipixel, and Arterys.
HeartFlow's Products & Differentiators
HeartFlow FFRct Analysis
The HeartFlow Analysis is a personalized cardiac test that leverages algorithms trained using deep learning and highly trained analysts to create a digital, personalized 3D model of the heart. The HeartFlow Analysis then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and provides FFRCT values along the coronary arteries. This information is used by physicians in evaluating the impact a blockage may be having on blood flow and determine the optimal course of treatment for each patient.
Loading...
Research containing HeartFlow
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned HeartFlow in 3 CB Insights research briefs, most recently on Jan 5, 2024.
Aug 1, 2023
The state of healthcare AI in 5 charts
Jul 26, 2023 report
State of Digital Health Q2’23 ReportExpert Collections containing HeartFlow
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
HeartFlow is included in 5 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,249 items
Tech IPO Pipeline
568 items
Digital Health 50
150 items
The most promising digital health startups transforming the healthcare industry
Digital Health
11,082 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Artificial Intelligence
6,855 items
HeartFlow Patents
HeartFlow has filed 377 patents.
The 3 most popular patent topics include:
- cardiology
- heart diseases
- cardiac arrhythmia
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/5/2022 | 10/22/2024 | Image processing, Image segmentation, Medical imaging, Socialism, Computer vision | Grant |
Application Date | 8/5/2022 |
|---|---|
Grant Date | 10/22/2024 |
Title | |
Related Topics | Image processing, Image segmentation, Medical imaging, Socialism, Computer vision |
Status | Grant |
Latest HeartFlow News
Oct 21, 2024
AMA Issues Category I CPT Code for AI-Enabled Plaque Quantification Technology October 18, 2024—HeartFlow, Inc., a developer of noninvasive artificial intelligence (AI) heart care solutions, announced that the American Medical Association (AMA) has issued a new Category I Current Procedural Terminology (CPT) code for AI-enabled plaque quantification technology, including the company’s HeartFlow Plaque Analysis, effective January 2026. The company noted that the AMA issued the new code in response to increased use of AI-enabled plaque quantification technology like the HeartFlow Plaque Analysis and strong clinical evidence supporting its value. According to HeartFlow, a Category III CPT code and payment were previously granted for Plaque Analysis in 2021. Along with the transition to a Category I code, the Centers for Medicare & Medicaid Services will establish relative value units for Plaque Analysis, which provides payment to physicians for performing the service. The successful conversion to a Category I code indicates that AI-enabled plaque quantification is considered consistent with current medical practice. The new reimbursement code complements the recently announced favorable coverage decision by four of seven Medicare Administrative Contractors, which will begin covering HeartFlow Plaque Analysis on November 24, 2024, advised the company. “We commend the AMA’s issuance of this upgraded Category I CPT billing code, which validates the technology’s clinical value in quantifying and characterizing plaque to help assess risk and personalize treatment for patients with coronary artery disease,” commented Campbell Rogers, MD, Chief Medical Officer of HeartFlow, in the press release. “It has been shown that with HeartFlow’s Plaque Analysis, two out of three patients had their medical management changed and more precisely tailored, which could contribute to better treatment decisions and improved outcomes.” Advertisement Subscribe to our weekly newsletter. Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.
HeartFlow Frequently Asked Questions (FAQ)
When was HeartFlow founded?
HeartFlow was founded in 2007.
Where is HeartFlow's headquarters?
HeartFlow's headquarters is located at 331 East Evelyn Avenue, Mountain View.
What is HeartFlow's latest funding round?
HeartFlow's latest funding round is Series F - II.
How much did HeartFlow raise?
HeartFlow raised a total of $757.41M.
Who are the investors of HeartFlow?
Investors of HeartFlow include U.S. Venture Partners, Martis Capital, HealthCor Management, Scottish Mortgage Investment Trust, Capricorn Investment Group and 13 more.
Who are HeartFlow's competitors?
Competitors of HeartFlow include Caristo Diagnostics and 7 more.
What products does HeartFlow offer?
HeartFlow's products include HeartFlow FFRct Analysis.
Who are HeartFlow's customers?
Customers of HeartFlow include Atrium Health.
Loading...
Compare HeartFlow to Competitors
Cleerly is a digital healthcare company that focuses on the treatment of heart disease. The company's main service is an AI-based digital care platform that works with coronary computed tomography angiography imaging to help clinicians identify and define atherosclerosis earlier, enabling them to provide personalized treatment plans. The platform measures atherosclerosis, or plaque build-up in the heart's arteries, and offers simpler, faster, and more accurate heart disease evaluation and reporting. It was founded in 2017 and is based in New York, New York.
Caristo Diagnostics specializes in advanced cardiovascular diagnostic tools within the healthcare technology sector. The company enhances the accuracy of routine cardiac computed tomography scans by identifying coronary inflammation and other hidden cardiac issues, which improves the prediction of cardiovascular risk and aids in treatment decisions. Its technology is utilized in preventive screening, disease diagnosis, intervention planning, and clinical research. The company was founded in 2017 and is based in Oxford, United Kingdom.
Artrya is a healthcare technology company that focuses on the application of artificial intelligence in the medical sector, specifically in the diagnosis of coronary heart disease. The company offers AI-driven solutions that assist in the rapid assessment of chest pain patients, providing insights into the type and volume of arterial plaque detected through coronary computed tomography angiography. This facilitates the accurate stratification of patients, enabling efficient patient intake and rapid discharge. It was founded in 2019 and is based in Crawley, Western Australia.
Elucid specializes in advanced arterial analysis software within the healthcare technology sector. The company offers software that provides objective and quantitative assessment of arterial plaque, validated by histology, to aid in the diagnosis and treatment of cardiovascular diseases. Elucid's software is designed to support physicians, patients, and clinical researchers by improving the accuracy of non-invasive testing and enabling personalized care. It was founded in 2013 and is based in Boston, Massachusetts.
CorVista Health specializes in cardiac diagnostics within the healthcare sector, focusing on the development of non-invasive, machine learning-powered diagnostic systems. It offers the CorVista System, a point-of-care diagnostic tool designed to accurately detect significant coronary artery disease (CAD) and pulmonary hypertension (PH) during a single patient visit. It aims to provide early diagnosis and intervention for cardiovascular diseases, leveraging advanced algorithms to analyze cardiac data and support treatment decisions. It was formerly known as Analytics 4 Life. The company was founded in 2012 and is based in Bethesda, Maryland.
CathWorks is a medical technology company that focuses on optimizing Coronary Artery Disease (CAD) therapy decisions through its advanced computational science platform. The company's main product, the FFRangio System, provides a quick, reliable intraprocedural physiologic assessment for the entire coronary tree, aiding physicians in making objective, wire-free FFR-guided PCI decisions. CathWorks primarily serves the healthcare industry, particularly in the field of cardiology. It was founded in 2013 and is based in Kfar-Saba, Israel.
Loading...